These findings enhance our understanding of ICC pathogenesis and reveal a novel cross‐talk mechanism between inflammation and tumorigenesis in cancer as well as establish FXYD3 as a highly promising diagnostic marker, prognostic indicator, and therapeutic target, paving a new path for precision therapy in ICC. Here, FXYD3 is linked to intrahepatic cholangiocarcinoma.